Formulation to De-Risk Solid-State Variation

WEBINAR

This webinar will present the concepts of crystal structure and polymorphism in drug development of oral solid dosage forms, will introduce CSP as an option to minimize solid-state risks, and, finally, will describe how mesoporous silica can be used as a last-resort technology to homogenize a solid form from exhibiting polymorphism. All of the above will be supported by a range of case studies from a diverse and highly relevant chemical space. Finally, we will propose an integrated workflow to combine computational and formulation technologies to optimize the development of orally delivered small molecules.

In this webinar, you will learn:

• The Importance of solid form in the development of orally delivered dosage forms
• How Crystal Structure Prediction (CSP) can be used to optimize solid form and identify challenging molecules
• Why mesoporous silica is an attractive formulation technology to homogenize particle properties
• About the combination of predictive and formulation technologies as a platform approach to solid formulation development